AI Verdict
GMED has stronger fundamentals based on our AI analysis.
GNPX vs GMED Fundamental Comparison
| Metric | GNPX | GMED |
|---|---|---|
| Revenue | $0.0 | $2.9B |
| Net Income | $-16.2M | $537.9M |
| Net Margin | N/A | 18.3% |
| ROE | -203.8% | 11.8% |
| ROA | -159.7% | 10.1% |
| Current Ratio | 3.84x | 4.26x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | N/A | $3.92 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
GNPX vs GMED: Frequently Asked Questions
Is GNPX or GMED a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), GMED has stronger fundamentals. GNPX is rated STRONG SELL (82% confidence) while GMED is rated BUY (78% confidence). This is not investment advice.
How does GNPX compare to GMED fundamentally?
Genprex, Inc. has ROE of -203.8% vs GLOBUS MEDICAL INC's 11.8%. Net margins are N/A vs 18.3% respectively.
Which stock pays higher dividends, GNPX or GMED?
GNPX has a dividend yield of N/A or no dividend while GMED has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in GNPX or GMED for long term?
For long-term investing, consider that GNPX has STRONG SELL rating with 82% confidence, while GMED has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about GNPX vs GMED?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GNPX vs GMED, the AI consensus favors GMED based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.